RESEARCH MONOGRAPH · KDC-MN-245
Topiramate
Topiramate (Topamax) is a sugar-derived anticonvulsant from Johnson and Johnson, approved by the FDA in 1996. It hits multiple targets at once: blocks sodium channels, potentiates GABA-A receptors, blocks AMPA glutamate receptors, and inhibits carbonic anhydrase. The mechanistic breadth makes it useful well beyond epilepsy. It is approved for migraine prevention, where it is one of the more effective options. It has substantial off-label use for weight loss because the carbonic anhydrase inhibition produces a metallic taste that suppresses appetite, and for alcohol use disorder where it appears to reduce craving. The side effect signature includes word-finding difficulty (the patient slang is dopamax), tingling in hands and feet, and kidney stone risk. Co-formulated with phentermine as Qsymia for obesity. Not stocked by Kodiac. This monograph is provided for research and educational reference.
Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.
Sulfamate-substituted monosaccharide / multifactorial anticonvulsant
A sulfamate-substituted monosaccharide anticonvulsant with broad mechanism (sodium channels, GABA-A potentiation, AMPA antagonism, carbonic anhydrase inhibition); used for migraine prophylaxis and weight loss.
Abstract
Topiramate (2,3:4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate; CAS 97240-79-4; molecular formula C12H21NO8S; molecular weight 339.36) is a sulfamate-substituted monosaccharide anticonvulsant developed at Johnson and Johnson and approved by the FDA in 1996 under the trade name Topamax. Mechanism is multifactorial: state-dependent sodium channel inhibition; GABA-A receptor potentiation at a non-benzodiazepine site; AMPA/kainate glutamate receptor antagonism; carbonic anhydrase inhibition (isozymes II and IV); high-voltage calcium channel inhibition. The carbonic anhydrase activity contributes to the characteristic adverse events: paresthesias (40 percent of patients), nephrolithiasis (1.5 percent), metabolic acidosis. Cognitive side effects are pronounced: word-finding difficulty, slowed mentation. Plasma half-life is 21 hours; metabolism is approximately 70 percent renal excretion unchanged. Approved for partial-onset and generalized tonic-clonic seizures, Lennox-Gastaut syndrome, migraine prophylaxis, and (with phentermine, as Qsymia) chronic weight management. Used as the canonical multifactorial anticonvulsant and as a reference carbonic anhydrase inhibitor in CNS pharmacology.
Mechanism of action
Multifactorial: sodium channel inhibition, GABA-A potentiation, AMPA antagonism, carbonic anhydrase inhibition. Used in epilepsy, migraine prophylaxis, and weight management.
Reported research dose ranges
Clinical 50 to 400 mg per oral administration daily. Rodent studies 10 to 100 mg/kg/day.
References
- Shank RP, et al. An overview of the preclinical aspects of topiramate. Epilepsia 2000.
- Silberstein SD, et al. Topiramate in migraine prevention. Headache 2007.
- Rosenfeld WE. Topiramate: a review of preclinical, pharmacokinetic, and clinical data. Clin Ther 1997.
Read the full monograph
The full reference document is available below as a PDF embed and download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.